MSF finds J&J ’s darunavir patent relaxation plan selective
This article was originally published in Scrip
Médecins Sans Frontières claims that Johnson and Johnson’s (J&J) recent announcement that in selective territories it would not assert it patents on its HIV/AIDS drug, darunavir, is limited in scope and ignores many countries where the company has patents for the drug.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.